证券代码：002773 证券简称：康弘药业 公告编号：2025-024 成都康弘药业集团股份有限公司 二〇二四年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"或"本公司"） 二〇二四年度权益分派方案已获公司 2025 年 5 月 21 日召开的二○二 四年度股东会审议通过，现将权益分派实施事宜公告如下： 一、股东会审议通过权益分派方案情况 2025 年 5 月 21 日，公司召开二〇二四年度股东会审议通过《二 〇二四年度利润分配预案》，二〇二四年度利润分配方案为：以 2025 年 4 月 25 日公司总股本 919,869,004.00 股为基数，向全体股东按每 10 股 派 发 现 金 红 利 6.00 元 （ 含 税 ） ， 共 计 派 发 现 金 红 利 551,921,402.40 元（含税）（919,869,004 股/10*6 元=551,921,402.40 元），剩余未分配利润结转至下一年度。 若分配预案公布后至实施前，公司股本总额由于股权激励行权、 可转债转股、股份回购等原因 ...

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

证券代码：002773 证券简称：康弘药业 公告编号：2025-023 成都康弘药业集团股份有限公司 关于子公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，成都康弘药业集团股份有限公司（以下简称"公司"）子 公司四川弘合生物科技有限公司（以下简称"弘合生物"）收到国家 药品监督管理局签发的《药物临床试验批准通知书》。现将相关情况 公告如下： 一、药品基本信息 药品名称：注射用 KH617 1 / 2 三、对公司的影响 由于药品从研发、临床试验、审评和审批的结果以及时间都具有 一定的不确定性，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 剂型：注射剂（冻干制剂） 适应症：与标准治疗方案联合治疗新诊断的胶质母细胞瘤 注册分类：化药 1 类 受理号：CXHL2500274 审批结论：同意本品开展临床试验 二、产品简介 注射用 KH617 是弘合生物合成生物学平台首个进入临床试验的 产品，属于化药 1 类创新药，I 期临床研究显示，注射用 KH617 安全 性和耐受性良好，且已初步观察到抗肿瘤的积极疗效信号，有望为胶 ...

中国成都市高新区天府一街 535 号两江国际 B 栋 33 层 61000 33/F, Building B, Twin Rivers International, No.535 Tianfu 1st Street, High-tech District, Chengdu 610000, China 电话 Tel: +86 28 6753 5588 传真 Fax: +86 28-6753 5588 电邮 Email: chengdu@tongshang.com 网址 Web: www.tongshang.com 关于成都康弘药业集团股份有限公司 二〇二四年度股东会之 法律意见书 北京通商(成都)律师事务所(以下简称"本所")接受成都康弘药业集团股份 有限公司(以下简称"公司")的委托，委派喻丹律师、周宇欣律师出席公司二〇 二四年度股东会(以下简称"本次股东会")，并根据《中华人民共和国公司法》 (以下简称"《公司法》")、《中华人民共和国证券法》等中国法律、法规及规范 性文件(以下简称"相关法律、法规"，为本法律意见书之目的，"中国"不包括香 港特别行政区、澳门特别行政区和台湾地区)以及《成都康弘药业集团股份 ...

成都康弘药业集团股份有限公司 二〇二四年度股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无否决议案的情况； 证券代码：002773 证券简称：康弘药业 公告编号：2025-022 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议的召开和出席情况 1、现场会议召开时间：2025 年 5 月 21 日（星期三）14:00。 2、现场会议召开地点：成都市金牛区兴科北路 20 号锦宾国际酒 店 会议中心 102 号会议室。 3、会议召开与投票方式：本次股东会采用现场表决与网络投票 相结合的方式召开。其中：通过深圳证券交易所交易系统进行网络投 票的具体时间为 2025 年 5 月 21 日 9:15—9:25，9:30—11:30 和 13:00 —15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 5 月 21 日 9:15-15:00。 4、召集人：成都康弘药业集团股份有限公司（以下简称"公司"） 董事会。 5、主持人：董事长柯尊洪先生。 6、会议的召集、召开与表决程序符合《中华人民共和国 ...

Market Performance - Major stock indices in China saw significant gains, with the North China 50 Index rising over 1% to reach a new high [1] - The FTSE China A50 Index futures increased by more than 1%, while the offshore RMB appreciated by 101 points against the USD, currently at 7.2041 [2] - The Shanghai Composite Index closed up 0.38% at 3393.49 points, with the Shenzhen Component Index up 0.53% and the ChiNext Index up 0.99% [2] Sector Highlights - The coal sector showed strong performance, with companies like Dayou Energy and Jinkong Coal Industry hitting the daily limit, and Shanmei International rising nearly 6% [2] - The solid-state battery concept gained traction, with companies like Lingpai Technology and Ningde Times seeing significant price increases, with Lingpai Technology hitting a 20% limit up [2][4] - The innovative drug sector remained active, with Shuyitai and SanSheng Guojian both hitting the daily limit, and SaiSheng Pharmaceutical rising over 12% [7] Company Developments - Ningde Times, which recently listed on the Hong Kong Stock Exchange, saw its stock rise by over 9% during trading [3] - Bubble Mart reached a new historical high, with its stock price rising over 5% to 220 HKD per share, bringing its market capitalization close to 300 billion HKD [10] - Bubble Mart's Labubu 3.0 product has gained immense popularity globally, leading to long queues in stores and significant price premiums on secondary markets [12] Industry Trends - The solid-state battery sector is identified as a core focus within the lithium battery industry, with companies actively launching new products and materials seeing increased demand [6] - The innovative drug market in China is projected to grow from 132.5 billion USD in 2019 to 159.2 billion USD by 2024, maintaining a global market share of around 15% [9]

伴随着西部A股上市公司披露了2024年年报，高管的薪酬情况随之曝光。 黄桷树财经整理了西部A股上市公司的10位"打工皇帝"。 第一位是创维数字（000810.SZ）副总经理张恩利。 张恩利，男，1979年出生，空军工程大学电力电子与电力传动专业硕士研究生学历，高级工程师，深圳市高层次后备级人才。 2024年，张恩利从创维数字获得的税前报酬总额为890.53万元。截至2024年末，张恩利持有2.5万股创维数字。 值得一提的是，张恩利虽然位列榜首，但他惨遭大幅降薪，2023年他的税前报酬是1482.2万元，2024年的税前报酬实际上降幅为40%。 第二位是重庆啤酒（600132.SH）总裁Lee Chee Kong（中文名：李志刚）。 Lee Chee Kong，男，53岁，马来西亚国籍，毕业于马来西亚北方大学工商管理专业。 在任职于嘉士伯前，Lee Chee Kong曾担任希丁安亚洲区总裁并兼任中国区董事总经理。更早前，他曾担任亨氏中国董事总经理职位，并且在高露洁棕榄 中国及亚太地区长时间从事管理工作。 2024年，龚晖从隆鑫通用获得税前报酬总额为639.91万元。截至2024年末，龚晖持有142.925万股隆 ...

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. is focusing on innovation and clinical needs to enhance its research and development efforts for its product pipeline in 2025 [1][2] Financial Performance - In 2024, the company achieved operating revenue of 4.453 billion yuan and a net profit attributable to shareholders of 1.191 billion yuan, representing year-on-year growth of 12.51% and 14.02% respectively [1] - In the first quarter of this year, the company reported operating revenue of 1.199 billion yuan and a net profit of 400 million yuan, with year-on-year increases of 9.7% and 7.09% respectively [1] Strategic Focus - The core competitive advantage of the company lies in its strategic layout and continuous innovation capabilities, which encompass product layout, research and development capacity, production capability, talent reserve, international development, and brand building [2] - The company has developed a diversified research and development system covering traditional Chinese medicine, antibody drugs, gene therapy, and small molecule drugs [2] Product Development - The company is advancing several innovative projects, including the "Shu Gan Jie Yu Capsule" for anxiety disorder in phase III clinical trials, and KH607 for depression in phase II clinical trials, as well as KH110 for Alzheimer's disease in phase III clinical trials [2] - KH815, a dual payload ADC drug, is the first of its kind to enter clinical trials globally, targeting advanced solid tumors with a dual mechanism of action [2] Future Direction - The company will continue to adhere to the business philosophy of "innovation as the core, quality as life" and will drive sustainable high-quality development through product innovation and industrial collaboration [3]

Group 1 - Feilong Co., Ltd. received a project designation notification letter from a well-known domestic automobile brand, becoming a supplier for a water-side thermal management module, with expected sales revenue during the lifecycle meeting disclosure standards [1] - Hanchuan Intelligent's controlling shareholder received a warning letter from Jiangsu Securities Regulatory Bureau for failing to timely disclose a share pledge contract, which may affect the company's control and stock price [2] - Vanke A completed the redemption of the "20 Vanke 04" corporate bonds, with a redemption amount of 1.5 billion yuan and interest payment of 51.75 million yuan [3][4] Group 2 - China Shenhua reported a 4% year-on-year decline in coal sales volume for April, totaling 35.6 million tons, and a 3.9% decrease in commodity coal production [5] - Shaanxi Black Cat plans to increase capital by 600 million yuan for its wholly-owned subsidiary Xinjiang Black Cat Coal Industry to enhance its capital strength [6][7] - China National Aviation reported an 8.6% year-on-year increase in passenger turnover for April, with a 5.3% increase in passenger capacity [8][9] Group 3 - Huabei Pharmaceutical's subsidiary received approval for clinical trials of a recombinant tetanus vaccine, which is a new generation vaccine with better safety and immunogenicity [10] - China Chemical's subsidiary received a lawsuit notice related to a securities false statement liability dispute [11] - China Metallurgical Group reported a 24.9% year-on-year decline in new contract value for January to April, totaling 308.4 billion yuan [13] Group 4 - Zhongmei Energy reported a 5.8% year-on-year decline in commodity coal sales for April, totaling 21.1 million tons [14] - Huangma Technology announced a plan to reduce holdings of up to 6.26 million shares due to personal funding needs [15] - Aiyingshi proposed a cash dividend of 2.53 yuan per 10 shares for the fiscal year 2024 [16] Group 5 - Shengyi Technology's executives plan to reduce their holdings by a total of 1.49 million shares [17] - CanSino's inhaled tuberculosis vaccine received clinical trial approval in Indonesia [18] - Beidouxingtong completed the acquisition of 51% of Shenzhen Tianli Automotive Electronics Technology Co., Ltd. [19] Group 6 - Spring Airlines reported a 12.29% year-on-year increase in available capacity for April, with a total of 4.73 billion ton-kilometers [20] - Dongya Pharmaceutical's raw material drug received registration certification in South Korea [21] - Shandong Steel plans to establish a sales subsidiary with a registered capital of 20 million yuan [22] Group 7 - Caida Securities appointed Hu Hengsong as the executive vice president [23] - Aibulu's vice president resigned due to personal career planning [24] - *ST Jinguang's stock price surged amid a warning of delisting risk [25] Group 8 - Yunnan Energy Investment plans to implement a 600,000 tons/year salt production energy-saving and carbon reduction project with a total investment of 448 million yuan [27] - Hanyu Group's executives plan to reduce their holdings due to personal funding needs [28] - Jiangsu Boyun's shareholders plan to reduce their holdings by up to 971,300 shares [29] Group 9 - Hainan Airport signed a cooperation agreement with Harbin Institute of Technology (Shenzhen) to establish a joint laboratory [32] - Xiamen Tungsten New Energy plans to acquire 47% of Ganzhou Haopeng Technology Co., Ltd. [33] - Dongfang Materials announced a change in controlling shareholder due to judicial auction of shares [34] Group 10 - Jingyuan Environmental Protection's executives plan to reduce their holdings by a total of 1.176% of the company's shares [35] - China Pacific Insurance reported a 10.4% year-on-year increase in original insurance premium income for the first four months [36] - ST United is planning a major asset restructuring and has suspended trading [37] Group 11 - *ST Suwu's chairman received a notice of investigation for suspected information disclosure violations [39] - Huagong Technology's subsidiary plans to establish a joint venture [40] - Qibin Group terminated the purchase of 28.78% equity in its subsidiary [41] Group 12 - Huakang Clean signed a construction contract worth 143 million yuan with Dengfeng City General Hospital [42] - Kanghong Pharmaceutical received approval for clinical trials of a drug for postpartum depression [43] - Shengjing Micro plans to repurchase shares worth between 30 million and 50 million yuan [44] Group 13 - Shenghe Resources' subsidiary plans to acquire 100% of Peak Rare Earths Limited for 158 million Australian dollars [45] - Sinopec's controlling shareholder increased its stake by 302 million H-shares, amounting to HKD 1.232 billion [46] - Mingyang Circuit plans to repurchase shares worth between 15 million and 25 million yuan [47] Group 14 - China Oil Engineering's subsidiary won a project in Iraq worth approximately 11.538 billion yuan [48] - Chaojie Co., Ltd. announced the termination of a share transfer agreement [49]

Core Viewpoint - Kanghong Pharmaceutical is actively advancing its drug pipeline, focusing on innovative treatments and maintaining a strong market position in the ophthalmology sector, particularly with its anti-VEGF product, Conbercept [1][3]. Group 1: Drug Development and Clinical Trials - The company is conducting a review for Lifisert eye drops at the National Medical Products Administration [1]. - KH109 and KH110 are in Phase III clinical trials, with KH109 already having completed subject enrollment and KH110 still in the process [1]. - KH110 aims to provide an innovative Chinese medicine solution for Alzheimer's disease, potentially enhancing the company's competitiveness in this therapeutic area [2]. - The clinical research for anxiety disorders using KH109 is progressing steadily, with completion of Phase III enrollment expected by April 2025 [1][2]. Group 2: Market Performance and Strategy - The company anticipates double-digit growth for Shugan Jieyu capsules in 2024, outpacing the overall antidepressant market growth [1]. - Kanghong Pharmaceutical has successfully entered multiple national procurement lists for its chemical drugs, including the Shongling Xue Mai Kang capsule, which has been selected in 23 provinces [2]. - The company is committed to increasing R&D investments across innovative drugs, traditional Chinese medicine, and chemical generics to provide high-quality, cost-effective products [2]. Group 3: Competitive Landscape - Conbercept has established itself as a leader in the Chinese anti-VEGF market, competing against top global brands [3]. - The company has a successful track record of overcoming challenges in the market, demonstrating confidence in maintaining its competitive edge [3]. - The incidence rates for the five major indications of anti-VEGF products are stable, suggesting consistent market demand [3]. Group 4: Management and Operational Efficiency - The company plans to enhance internal control management and performance evaluation to improve overall management efficiency [4]. - There is a focus on advancing infrastructure projects for planned production and improving brand promotion and marketing management [4]. - Financial management will be strengthened, with an emphasis on cost control, budget execution, and monitoring of fund operations to mitigate financial risks [4].